Search for: "CIPLA"
Results 61 - 80
of 202
Sort by Relevance
|
Sort by Date
5 Jun 2012, 10:47 am
Cipla Ltd., the Federal Circuit recently reviewed an appeal from the Middle District of Georgia that found defendant Cipla (an Indian company) in contempt for violating an earlier injunction and finding co-defendant Velcera in contempt for acting in concert with Cipla to violate that injunction. [read post]
4 Jun 2012, 3:00 am
CIPLA Ltd., et al., Nos. 2011-1471, 1472 (Fed. [read post]
2 Jun 2012, 12:50 pm
Cipla, Ltd., 2012 U.S. [read post]
31 May 2012, 9:00 pm
CIPLA Ltd., et al., Nos. 2011-1471, 1472 (Fed. [read post]
31 May 2012, 11:30 am
Cipla, the majority stated we conclude that (1) the 2008 default judg- ment against Cipla rested on a valid exercise of personal jurisdiction; (2) the district court did not abuse its discretion by declining to stay the contempt proceedings in view of the then-pending Delaware action; (3) the district court did not clearly err in determining that PetArmor Plus infringes the ’329 patent and is not more than colorably different from Cipla’s previously enjoined… [read post]
6 Apr 2012, 2:00 pm
CIPLA Announcement.pdf (42.80 kb) [read post]
3 Apr 2012, 8:57 pm
The case of Adcock Ingram v Cipla Medpro reconsidered the notion that pharmaceuticals sold on prescription are less likely to be confused because they are dispensed by trained professionals in regulated circumstances. [read post]
30 Mar 2012, 6:48 pm
Sun Pharmaceuticals is recalling about 155,000 bottles of an eye solution, while two of Cipla's top pharma partners have pulled products made at its Goa plant.Read more: Drugs made by Sun Pharma, Cipla recalled in U.S. - FiercePharma http://www.fiercepharma.com/story/drugs-made-sun-pharma-cipla-recalled-us/2012-03-29#ixzz1qeeymDe5 http://articles.economictimes.indiatimes.com/2012-03-29/news/31254546_1_fda-s-class-iii-bottles-cancer-drug [read post]
14 Mar 2012, 10:00 pm
Bayer has sued that company, Cipla, which is based in Mumbai, claiming patent infringement in a separate case that is pending. [read post]
14 Mar 2012, 10:00 pm
Bayer has sued that company, Cipla, which is based in Mumbai, claiming patent infringement in a separate case that is pending. [read post]
14 Mar 2012, 6:40 am
Bayer argued that Cipla's sales should be considered when deciding whether the reasonable requirements of the public were being satisfied (even though Cipla were being sued by Bayer for these actions). [read post]
25 Jan 2012, 12:54 pm
Issues re Non-US Online Infringement Litigation Domain Name In Rem: Decker v 2011cheapuggs.com, (ED Va Jan 6, 2012) Order. [read post]
8 Dec 2011, 11:16 am
The lawsuit reported by my dog Ollie here is said to be settled here. [read post]
14 Sep 2011, 6:22 am
Plaintiff alleges that Indian generic pharma CIPLA (covertly) manufactures DA DOUBLE ADVANTAGE and conspires to sell it into the US through several offshore websites. [read post]
15 Jul 2011, 7:40 am
It is also manufactured and marketed by Cipla under trade name Tiova. [read post]
29 Jun 2011, 3:34 am
(Patent Docs) Deferacirox – India: Cipla wins pre grant opposition (593/CHENP/2005): Novartis v. [read post]
27 Jun 2011, 11:47 am
pricing debate (Roche vs Cipla), Compulsory Licensing: Export of patented drugs (Pfizer/ Roche vs Natco), Linkages in Indian Patent System (Custom enforcement, Biopharmaceuticals, Marketing –Approval and EMR, Efficacy testing, Competition, Working). [read post]
6 Apr 2011, 12:18 am
Laboratorios Rubió (EPLAW) Gemzar (Gemcitabine) – US: ITC: Target date of 23 July 2012 set in Certain Gemcitabine (ITC 337 Law Blog) Intuniv (Guanfacine) – US: Shire files patent infringement complaint based on Mylan’s ANDA filing (Patent Docs) Isentress (Raltegravir) – India: Cipla files for compulsory license against Merck’s Isentress (Spicy IP) Losartan, HCTZ – France: Cour d’appel confirms combination products infringe mono-SPCs and… [read post]
22 Mar 2011, 4:21 pm
: Board of Trustees of Leland Stanford Junior University v Roche Molecular Systems Inc (IPKat) US: That was unexpectedly… well… expected: BPAI affirms Examiner’s obviousness rejection in Ex Parte Akio Ochiai concerning a health food product containing curcumin, scymnol and isoflavones (BT-IP Notes) US: VirginiaTech VERSUS series – Drug evaluation DVDs available (FDA Law Blog) Products Diovan HCT (Valsartan, Hydrochlorothiazide) – Germany: Düsseldorf… [read post]
8 Jan 2011, 2:18 pm
The Application was refused after Bayer failed to overcome the pre-grant oppositions filed against the Application by generic manufacturers Cipla [read post]
